

BioBusiness Asia 2009

| | | | |
|--------------------|---|--------------------|-----------|
| Company Name | NatureWise Biotech & Medicals Corporation | | |
| Presenter | Chung Yang Huang | Title | President |
| Address | 3F, 216 Wenlin North Road, Peitou, Taipei 112, Taiwan | | |
| Website | www.naturewise.com.tw | | |
| No. of employee | 27 | Year of foundation | 2000 |
| Company Categories | <input type="checkbox"/> Novel Therapeutics <input type="checkbox"/> Genomics Pharmaceuticals <input type="checkbox"/> R&D Service <input type="checkbox"/> Medical Devices <input type="checkbox"/> Other _____ | | |
| Paid-in Capital | NT\$157,000 thousand | | |
| Company Stage | <input type="checkbox"/> Seed <input type="checkbox"/> Start up Expansion <input type="checkbox"/> Mezzanine | | |
| Company Overview | <p>NatureWise Biotech & Medicals Corp.(NBM) is a listed drug discovery/development company. The company is also a health dietary supplement and herbal product provider. LipoCol Forte, a product for the treatment of hypercholesterolemia and hypertriglyceridemia, was the first product in Taiwan to receive a 'Drug Certificate of New Chinese Medicine' from Taiwan's Department of Health. It is the first TCM drug in Taiwan to complete Phase III trials in accordance with GCP guidelines. NBM's R&D focuses on HDAC inhibitors and neurotropic / neurotrophic compounds. The company received a number of awards for its R&D achievements and products including Gold Place from Taipei Biotech Award.</p> | | |

| | |
|--|--|
| <p>Company History</p> | <ul style="list-style-type: none"> ■ NatureWise Biotech & Medicals Corp. (NBM) was founded in December, 2000 and listed in the Emerging Market Exchange Board in December, 2007. ■ 2005, New Drug Certificate of LipoCol Forte® was issued by the Department of Health of Taiwan. It was the first Traditional Chinese Medicine to receive such a certificate in Taiwan. ■ 2005, LipoCol Forte® received The Award of Best Commercialization of Biotechnology by Taipei City Government. ■ 2006, received SBIR research grants for “ Development of the novel supplements on the serum-free media and “ Studies on enhancing the production of propolis ” from Ministry of Economic Affairs. ■ 2007, received SBIR research grants for “ Development of the novel HDAC inhibitor against several cancer types from Ministry of Economic Affairs. ■ 2007, Patents of “ compounds for the inhibition of histone deacetylase ” were filed in Taiwan, Japan, China, Australia, EU and USA. ■ 2007, “ The development of HDAC inhibitor, a novel anti-cancer drug ” received the Gold Plate of The Best R&D Innovation Award by Taipei City Government. ■ 2008, PPLs, a novel neurotrophic factor, received The Award of Best Commercialization of Biotechnology by Taipei City Government. ■ 2008, “ compounds for promoting the growth of neural cells” received patent in Taiwan. ■ 2008, PPLs won the Bronze Medal of National Biotechnology & Medical Care Quality Award. ■ 2009, a clinical trial of “The Efficacy of PPLs for the Treatment of Mild Alzheimer Disease” was conducted in Taipei Medical University Hospital. |
| <p>Main Products/ Service & Niche of Products/ Service</p> | <ul style="list-style-type: none"> ■ Anti-hyperlipidemia products <ul style="list-style-type: none"> ➤ LipoCol Forte® ■ Anti-dementia products <ul style="list-style-type: none"> ➤ IQBLESS ■ Anti-Diabetes Mellitus products <ul style="list-style-type: none"> ➤ SUGARBLESS |

| | |
|--|--|
| Market Potentials | <p>Anti-hyperlipidemia drug market</p> <ul style="list-style-type: none"> ■ According to IMS, cholesterol-lowering drugs were the world’s No. 1 selling drug in 2004 with sales reaching US\$30bn. ■ Total sales of Taiwan’s cholesterol-lowering drug topped NT\$2.6bn and reached NT\$3.2bn in 2005. ■ NBM’s LipoCol Forte® was the first TCM that received a new drug certificate from the DOH with the indication of “lowering high cholesterol and triglyceride.” ■ With good scientific evidence and safety profile, LipoCol Forte® is gaining great acceptance among Western and Chinese physicians. <p>Anti-neurodegenerative drug market</p> <ul style="list-style-type: none"> ■ According to the report by Business Insights, the market of anti-neurodegenerative drugs for dementia and Parkinson diseases, was around US\$50bn. ■ The number of dementia patients was 25 million in 2006, and is expected to reach 80 million in 40 years. At present, there is still no drug that can “cure” neurodegenerative diseases. ■ The pharmacology of PPLs shows that it has a great potential to be developed into an anti-neurodegenerative drug. PPLs have the following features: <ul style="list-style-type: none"> - Differentiation : PPLs induce brain stem cells to differentiate into neurons. - Neurogenesis : PPLs enhance the outgrowth of neurite - Antioxidation : PPLs protect brain cells from the damage of free radicals ■ Clinical study is currently conducted at Taipei Medical University Hospital to investigate the effect of PPLs in patients with dementia. <p>Anti-diabetes mellitus drug market</p> <ul style="list-style-type: none"> ■ The number of diabetes patients was more than 1.9 billion in 2006, and is expected to reach 3.3 billion in 2025. ■ Although there are many diabetic drugs in the market, they all have various side-effects such as weight gain, edema, liver toxicity and some even increase the risk of heart attack. ■ SUGARBLESS is a comprehensive natural product for DM patients with few known side effects. |
| Company Core Competence or Competitive Advantage | <ul style="list-style-type: none"> ■ NatureWise has experience in conducting clinical trials of Traditional Chinese Medicine under GCP Guidelines. ■ One of the few companies in the research of HDAC inhibitors. ■ Finding new drug candidates from natural sources. ■ Innovative natural product development for diseases related to aging such as neurodegenerative, cardiovascular, diabetic, and postmenopausal diseases. |
| Partnering Objectives | <ul style="list-style-type: none"> ■ Finding overseas distributors ■ Technology licensing opportunity |